Hodgkin Lymphoma: Comprehensive Diagnosis and Treatment
Diagnosis
The diagnosis of Hodgkin lymphoma requires an excisional lymph node biopsy with immunohistochemistry showing CD30+ and CD15+ Reed-Sternberg cells that are typically CD45- and CD3- 1, 2. Core needle biopsy may be adequate if diagnostic, but fine-needle aspiration alone is insufficient except when combined with immunohistochemistry and reviewed by an expert hematopathologist 1.
Mandatory Diagnostic Workup
Imaging:
- PET/CT scan from skull base to mid-thigh (essential for initial staging) 1, 2
- Contrast-enhanced CT of neck, chest, abdomen, and pelvis 3
- Chest X-ray (particularly for large mediastinal masses) 3
Laboratory Tests:
- Complete blood count with differential and platelets
- Erythrocyte sedimentation rate (ESR)
- LDH, albumin, liver and renal function tests
- Alkaline phosphatase, glucose, TSH 3
- HBV, HCV, and HIV screening 1
Additional Required Assessments:
- Bone marrow biopsy (mandatory per ESMO guidelines) 3
- ECG and echocardiography (pre-treatment cardiac assessment)
- Pulmonary function tests
- Fertility preservation counseling for all young patients of both genders before treatment 3
Note: Staging laparotomy is NOT recommended 3.
Risk Stratification
Patients are classified into three risk groups based on Ann Arbor/Cotswolds staging and specific risk factors 3:
Limited Stage (Early Favorable)
- Stage I-II supradiaphragmatic WITHOUT risk factors
Intermediate Stage (Early Unfavorable)
- Stage I-II WITH ≥1 risk factors:
- Large mediastinal mass (>1/3 maximum horizontal chest diameter)
- Elevated ESR (>50 mm/h without B-symptoms; >30 mm/h with B-symptoms)
- Age ≥50 years (EORTC) or extranodal disease (GHSG)
- ≥3-4 nodal areas involved
Advanced Stage
- Stage III-IV
- Stage IIB with large mediastinal mass or extranodal disease
B-symptoms include: unexplained fever >38°C, drenching night sweats, weight loss >10% body weight within 6 months 1.
Treatment by Stage
Limited Stage (Early Favorable)
Standard treatment: 2 cycles of ABVD followed by 20 Gy involved-site radiotherapy (ISRT) 4, 2. This represents the least toxic effective approach with excellent disease control 2.
ABVD regimen (days 1 and 15, recycle day 29):
- Doxorubicin 25 mg/m²
- Bleomycin 10 mg/m²
- Vinblastine 6 mg/m²
- Dacarbazine 375 mg/m²
Alternative PET-guided approach (based on EORTC H10 study):
- 2 cycles ABVD → interim PET
- If PET-negative (Deauville ≤2): 1 additional cycle ABVD + 20 Gy ISRT
- If PET-positive: 2 cycles BEACOPPescalated + 30 Gy ISRT 2
Critical caveat: While PET-negative patients may be considered for chemotherapy-only approaches, randomized trials consistently show superior progression-free survival with combined modality treatment. Omitting radiotherapy should only be considered when late RT toxicity risks clearly outweigh benefits 2.
Intermediate Stage (Early Unfavorable)
For patients ≤60 years, two evidence-based options exist:
Option 1 (Standard): 4 cycles ABVD + 30 Gy ISRT 3
Option 2 (More intensive): 2 cycles BEACOPPescalated + 2 cycles ABVD + 30 Gy ISRT 3
- Provides superior freedom from treatment failure at 4 years
- However, long-term toxicity data (especially infertility) are lacking 3
- Consider for younger patients eligible for intensive treatment
For patients >60 years: 4 cycles ABVD + 30 Gy ISRT (avoid BEACOPP due to increased toxicity) 3
BEACOPPescalated regimen (recycle day 22):
- Bleomycin 10 mg/m² (day 8)
- Etoposide 200 mg/m² (days 1-3)
- Doxorubicin 35 mg/m² (day 1)
- Cyclophosphamide 1250 mg/m² (day 1)
- Vincristine 1.4 mg/m² (day 8)
- Procarbazine 100 mg/m² (days 1-7)
- Prednisone 40 mg/m² (days 1-14)
- Requires G-CSF support 3
Advanced Stage (III-IV)
The treatment choice depends on age and tolerance for intensive therapy:
Patients ≤60 Years:
Two main options with different risk-benefit profiles:
Option 1: 6-8 cycles ABVD 3
- 6 cycles if complete remission after 4 cycles
- 8 cycles if partial remission after 4 cycles
- Long-term cure rates 50-60%
- Better tolerated, less acute toxicity
Option 2: 8 cycles BEACOPPescalated 5
- Superior overall survival (92% at 5 years) and disease-free survival (88%) 5
- Superior freedom from treatment failure compared to ABVD
- Considered standard by German Hodgkin Study Group for patients <60 years 5
- Significantly higher toxicity requiring G-CSF support 3
Radiotherapy in advanced stage:
- 30 Gy localized RT to residual lymphoma >1.5 cm after chemotherapy 3
- May be omitted if residual lymphoma is PET-negative after chemotherapy 3
- Not generally recommended for residual disease <2.5 cm 5
Patients >60 Years:
6-8 cycles ABVD + 30 Gy RT to residual masses >1.5 cm 3
- BEACOPP should NOT be used in elderly patients due to increased toxicity 3
Important consideration: While BEACOPPescalated offers superior disease control and overall survival in younger patients, the increased acute toxicity (including potential infertility) must be weighed against the excellent salvage options available for ABVD failures. The choice should consider patient age, comorbidities, and fertility concerns.
Relapsed/Refractory Disease
For younger patients with relapsed disease after combined modality treatment:
Standard approach: Salvage chemotherapy → high-dose chemotherapy (HDCT) → autologous stem cell transplantation (ASCT) 5
Established salvage regimens:
- DHAP (dexamethasone, high-dose cytarabine, cisplatin)
- ESHAP (etoposide, methylprednisolone, high-dose cytarabine, cisplatin)
- ICE (ifosfamide, carboplatin, etoposide)
- MiniBEAM
- Gemcitabine-based combinations
- Typical approach: 2 cycles DHAP followed by BEAM conditioning 5
For patients relapsing after ASCT:
- Gemcitabine alone or in combination (palliative intent) 5
- Allogeneic transplant remains experimental and should be performed within clinical trials for chemotherapy-sensitive younger patients with suitable donors 5
Special populations:
- Rituximab is effective for CD20-positive HL (usually nodular lymphocyte-predominant HL) 5
- Stage I nodular lymphocyte-predominant HL can be treated with 30 Gy involved-field RT alone 5
Response Evaluation and Follow-Up
Response evaluation:
- Performed after completion of treatment and when clinically indicated 5
- Physical examination, laboratory analysis, CT scans of initially involved areas
- PET can distinguish active from non-active tissue but requires confirmation in prospective trials 5
Follow-up schedule:
- Every 3 months for year 1
- Every 6 months for years 2-3
- Annually thereafter 5
Surveillance includes:
- History, physical examination, laboratory analysis
- CT scan to confirm complete remission; additional scans only for residual disease evaluation 5
- Women receiving breast tissue radiotherapy: clinical breast screening and mammography starting at age >40 years 5
Critical Pitfalls to Avoid
Do not use fine-needle aspiration alone for diagnosis – inadequate for architectural assessment 1
Do not perform staging laparotomy – outdated and unnecessary 3
Do not use BEACOPP in patients >60 years – excessive toxicity without proven benefit 3
Do not omit fertility counseling – must be addressed before treatment initiation 3
Do not routinely radiate residual masses <1.5-2.5 cm in advanced stage unless PET-positive 3, 5
Interim PET-guided treatment de-escalation remains investigational – multiple trials show PFS advantage for combined modality despite negative interim PET 2
Do not assume all residual masses require radiation – PET-negative residual lymphoma after chemotherapy may not need RT 3